KDOQI对美国KDIGO 2025儿童肾病综合征管理指南的解读
KDOQI工作组审阅了KDIGO 2025儿童肾病综合征管理指南,并结合美国临床实践提供实施视角。更新指南反映美国当代实践,与IPNA 2020和2022指南协调,强调密切监测和疾病状态刻画。美国尿试纸保险覆盖不足是管理障碍,遗传检测整合和高危CKD患者管理需补充实践要点。
要点
- 密切监测和疾病状态刻画是儿童肾病综合征治疗决策的核心。
- 美国尿试纸缺乏保险覆盖是优化疾病管理的显著障碍。
- 指南实践要点有助于医患共同决策,但需补充遗传检测整合等内容。
核心结论
- 更新指南反映美国当代实践,与IPNA指南协调,强调密切监测和疾病状态刻画。
- 美国尿试纸保险覆盖不足是优化管理的显著障碍。
- 指南实践要点有助于医患共同决策,但需补充遗传检测整合及高危CKD患者管理要点。
研究设计与样本
- KDOQI召集工作组审阅KDIGO 2025儿童肾病综合征管理指南声明和实践要点。
- 工作组结合美国临床实践背景提供实施视角。
主要发现
- 更新指南与IPNA 2020和2022指南协调。
- 密切监测和疾病状态刻画仍是治疗管理决策核心。
- 美国尿试纸缺乏保险覆盖是显著障碍。
- 更多治疗选择出现,实践要点有助于医患共同决策。
临床怎么用
- 临床应重视密切监测和疾病状态刻画以指导治疗决策。
- 需关注尿试纸保险覆盖问题对管理的影响。
- 可利用实践要点促进医患共同决策。
局限性
- 指南未包含遗传检测结果整合入治疗决策的实践要点。
- 指南未包含继发性SRNS和APOL1高危基因型CKD患者的管理要点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2025 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. The KDOQI work group reviewed the KDIGO guideline statements and practice points and provided perspective for implementation within the context of clinical practice in the United States. The updated guidelines reflect contemporary US practice and offer highly relevant guidance that is harmonized with the International Pediatric Nephrology Association's guidelines published in 2020 and 2022. A focus on close monitoring and characterization of the disease status for children with nephrotic syndrome remains central to treatment and management decisions, noting that the lack of insurance coverage for urine dipsticks in the United States is a significant barrier to optimal disease management. As more treatment options become available to children with nephrotic syndrome, the detailed practice points are a sound tool to help providers engage patients and their families in joint decision making. The clinical utility of the guidelines would be enhanced by inclusion of practice points on the incorporation of genetic testing results into treatment decisions, as well as factors to consider when treating and managing patients at high risk for progression to end-stage kidney disease-those with secondary steroid-resistant nephrotic syndrome and those with the chronic kidney disease high-risk APOL1 genotype. The research needs detailed in the updated guidelines reflect the exciting direction of the practice landscape to provide patient-centered, precision-based care.
引用
- Wang CS, Gbadegesin R. KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Am J Kidney Dis. 2026. PMID: 41577383. doi:10.1053/j.ajkd.2025.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。